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An idiotype is an antigenicdeterminantunique (private) to a given antibody mol-
ecule and is associated with the antigen combining site of the antibody. Crossreac-
tive idiotypes are shared antigenic determinants between antibodies of different an-
tigenic specificities in one individual or among antibodies against the same antigen
in different individuals .
Monoclonal IgM rheumatoid factors were the firstautoantibodiesknownto share
idiotypic reactivity (1). Shared idiotypy has also been demonstrated for autoanti-
bodies found in autoimmune disorders, includinghuman (2) and murine lupus (3).
In systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS)' shared idi-
otypes have been described forantibodies to DNA (2), Sm (4), and IgG (rheumatoid
factor) (5) . Anti-DNA idiotypes have been related to Ig deposition in the kidneys
ofSLE patients and mice (6, 7) . Idiotypic specificities are consequently thought to
reflect the pathogenic potential of autoantibodies in this disease.
Autoantibodies to theRNA protein antigens Ro/SSA and La/SSB are also very
common in SLE and SS, often present in serum concentrations >1 mg/ml . These
autoantibodies are associated with differences in disease expression (8) . To date, there
has been little success in defining idiotypic characteristics ofthese antibodies . Only
private idiotypes have been reported for anti-La/SSB in humans (9) and none have
been characterized for anti-Ro/SSA . To examine anti-Ro/SSA idiotypes, we pre-
pared a heterologous rabbit antiidiotype to anti-Ro/SSA F(ab')2 affinity purified
from the serum of a precipitin positive individual and evaluated the possibility of
crossreactive idiotype between anti-Ro/SSA+ individuals .
Materials and Methods
Serum Samples .
￿
Sera from 13 female donors with precipitating levels of anti-Ro/SSA were
collected and stored at -20°C . Anti-Ro/SSA levels were quantitatedby ELISA as previously
described (10-12) .
Anti-Ro/SSA Purification .
￿
Anti-Ro/SSA was prepared from serum by affinity chromatog-
raphy as previously described (11) . Theprotein yield was N1 mg of antibody permg ofRo/SSA
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coupled. Anti-Ro/SSA previously purified and characterized from a normal male donor (11)
was also included in this study.
Antiidioype Production.
￿
Immune serum against anti-Ro/SSA (antiidiotype) was made by
injecting a New Zealand white female rabbit with affinity-purified F(ab')2 fragments of anti-
Ro/SSA from a patient. F(ab')2 fragments of serum anti-Ro/SSA were prepared as previously
described (12), and 300 p.g in 1 ml CFA was injected intramuscularly and subcutaneously
into a rabbit. The animal was boosted at 25 d with 300 wg anti-Ro/SSA F(ab')2 in 1 ml IFA
and again after 50 d with 300 pg in saline. The rabbit was bled after 7 wk and subsequent
sera were collected over a 4-mo period.
Antiidiotype Purification.
￿
Antiidiotype was purified from the immune rabbit serum by affinity
chromatography. Affinity-purified anti-Ro/SSA IgG (ti7 mg) was coupled to Sepharose 4B.
The immune rabbit serum was dialyzed into Tris buffer and passed over the anti-Ro/SSA
column twice. The bound antibody was washed, eluted, and dialyzed in Tris buffer. The purified
rabbit Ig was absorbed extensively with Cohn Fraction II IgG (Sigma Chemical Co., St. Louis,
MO) coupled to Sepharose to remove reactivity against public framework epitopes.
Enzyme-linked Immunosorbent Assay (ELISA).
￿
The antiidiotypic activity of the rabbit anti-
body was detected by a solid-phase enzyme immunoassay modified from methods previously
described (12). Briefly, microtiter plates were coated with purified anti-Ro/SSA at 1-2 Fag/ml.
Absorbed rabbit antiidiotype (0.1-10 1~g/ml) or normal rabbit serum (10-s-10-6 dilutions)
were added to the anti-Ro/SSA-coated plates. Antiidiotype binding was detected with goat
anti-rabbit IgG-alkaline phosphatase conjugate crossabsorbed with human serum proteins
to decrease nonspecific binding (Sigma Chemical Co.). Wells were developed withp-nitrophenyl
phosphate and optical densities determined. The specificity of the rabbit antiidiotype was
confirmed by blocking assays where antiidiotype was preincubated with increasing concen-
trations (0.01-100 Fig/ml) of anti-Ro/SSA IgG and F(ab')2 or Cohn Fraction II IgG. The in-
cubation mixtures were then added to anti-Ro/SSA IgG-coated plates and developed as de-
scribed above.
The reverse assay was used to further characterize the anti-Ro/SSA idiotype (Id-Rol). Ab-
sorbed rabbit antiidiotype (5 ttg/ml) was coated followed by 3 lAg/ml anti-Ro/SSA and goat
anti-human IgG-alkaline phosphatase conjugate (Sigma Chemical Co.). The conjugate was
mixed with a 1 :100 dilution of normal rabbit serum to decrease nonspecific binding. Addi-
tional conjugates used included goat anti-human 14, a, K, and Xchain-specific reagents. Blocking
assays were performed where 3 p,g/ml anti-Ro/SSA IgG was preincubated with 1-30 hg/ml
purified Ro/SSA for 2 h at room temperature before being added to the rabbit antiidiotype
coated plate.
Western Blot.
￿
SDS-PAGE was performed under nonreducing conditions using the Phast
System (Pharmacia Fine Chemicals, Uppsala, Sweden). 100 ng per lane of Cohn Fraction
II IgG or affinity-purified anti-Ro/SSA in 2 17o SDS and 10% glycerol were each electropho-
resed in an 8-20% gradient gel (Pharmacia Fine Chemicals) for 30 min at 15°C . The gel
was then overlayed with nitrocellulose paper and the proteins were heat transferred for 20 min
at 70'C. The immunoblot was blocked overnight in 0.02 M Tris buffer, 0.15 M NaCl, 0.02 %
azide, pH 8.0, with 0.05% Tween-20 and 2 % nonfat dry milk. Each incubation was at room
temperature with shaking. The nitrocellulose strips were then incubated with 10 FZg/ml ab-
sorbed rabbitantiidiotype for 1 h. After several 5-min washes of Tris buffer with Tween-20,
the blots were incubated with anti-rabbit IgG-alkaline phosphatase conjugate for 1 h. The
protein bands were developed with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue
tetrazolium according to the Protoblot Immunoblotting System (Promega Biotec, Madison,
WI). Positive control lanes were blotted with anti-human IgG-alkaline phosphatase and con-
jugate control lanes were developed only with anti-rabbit IgG-alkaline phosphatase followed
by substrate.
Results and Discussion
To study anti-Ro/SSA idiotypes, a rabbit was immunized with affinity-purified
anti-Ro/SSA F(ab')2 . The immunogen had no Fc reactivity by solid-phase ELISA.
The resulting antiidiotype was purified from rabbit serum by affinity chromatog-E c
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raphy and absorbed extensively with Cohn fraction II IgG. The absorbed rabbit
antiidiotype anti-Id-Rol was specific for the anti-Ro/SSA F(ab')2 immunogen and
did not bind normal human IgG as shown by inhibition ELISA in Fig. 1. The an-
tiidiotype was blocked by anti-Ro/SSA IgG and F(ab')2 but not by normal human
IgG. Conversely, purified anti-Ro/SSA did not bind normal rabbit serum when tested
by ELISA (data not shown).
When assayed by ELISA forisotype, the idiotype (Id-Rol) waspresent on 'y heavy
chains with either « or X light chains. This suggests a heavy chain location for Id-
Rol, as idiotype-positive IgG consisted of both light chain types (data not shown).
A competition ELISA was used to determine whether the anti-Ro/SSA idiotype
was associated with the Ro/SSA binding site. When anti-Ro/SSAwas incubated with
Ro/SSA, the bindingofrabbit antiidiotype and Id-Rol wascompletely blocked(Fig.
2). This indicates that the location of Id-Rol on anti-Ro/SSA is in or close to the
antigen binding site of anti-Ro/SSA.
The anti-Ro/SSA specificity of the antiidiotype was additionally confirmed by
Westernblotting. The anti-Id-Rol boundanti-Ro/SSA IgG but did not bind an equal
amount of normal human IgG under nonreducing conditions (Fig. 3). Anti-ld-Rol
activity was dependent upon the conformational Ig structure for binding, as anti-
Ro/SSA was not bound under reducing conditions .
Anti-Ro/SSA was affinity purified from the serum of 12 additional anti-Ro/SSA
precipitin-positive donors. Each anti-Ro/SSA preparation was then tested by ELISA
1 3 10 30
pg/ml RoSSA (loglo conc)
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FIGURE 1.
￿
Binding specificity of the absorbed rabbit
antiidiotype. Rabbit anti-Id-Rol was incubatedwith in-
creasing amountsofCohn Fraction II IgG(/), affinity-
purified anti-Ro/SSA IgG(0), andaffinity-purifiedanti-
Ro/SSA F(ab')2 (A). Both IgG and F(ab')2 anti-Ro/SSA
completely inhibited binding of anti-Id-Rol to anti-
Ro/SSA IgG in thesolid-phase ELISA. Cohn Fraction
II IgG was unable to inhibit anti-Id-Rol binding to
anti-Ro/SSA.
FIGURE 2.
￿
Inhibition of idiotype-antiidiotype interaction with
Ro/SSA antigen. Affinity-purified anti-Ro/SSA IgG wasincubated
with increasing amounts of purified Ro/SSA before beingadded
to the anti-Id-Rol-coated microtiter plate. Ro/SSA completely
blocked the anti-Ro/SSA/anti-Id-Rol binding.1586
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FIGURE 3 .
￿
Western blot ofCohn Fraction II IgG and anti-
Ro/SSA IgG with anti-Id-Rol . Lanes 1, 3, and 5 contain
Cohn Fraction II IgG and lanes 2, 4, and 6 contain affinity-
purified anti-Ro/SSA IgG . Lanes 1 and 2 were blotted with
anti-human IgG to detect total IgG . Lanes 3 and 4 were
developed with rabbit anti-Id-Rol followed by anti-rabbit IgG
conjugate, while lanes 5 and 6were developed with rabbit
conjugate alone as a control . The anti-Id-Rol bound anti-
Ro/SSA IgG (lane 4) but not Cohn fraction II IgG (lane 3) .
for reactivity with the rabbit anti-Id-Rol. 3 of the 12 additional anti-Ro/SSA+
women shared varyingdegreesof reactivity with theantiidiotype as shown byELISA
in Table I .
In a previous report (11), we affinity purified anti-Ro/SSA from the serum of a
normal donor with low levels of anti-Ro/SSA. This antibody was tested and also
crossreacted with the prepared rabbit antiidiotype (Table I) .
This study is the first report of a shared anti-Ro/SSA idiotype. Crossreactiveidio-
types have been described for anti-Sm,anti-DNA, and rheumatoid factor, but none
TABLE I
Reactivity ofAnti-Id-Rol with Affinity-purled Anti-Ro/SSA
from 12 Additional Patients and a Normal Serum
Anti-Ro/SSA'
￿
Anti-Ro/SSA
￿
Id-Rol activity of anti-Ro/SSA IgG
patients
￿
serum units
￿
OD
￿
Score'
DC1
￿
3.01 x 10'
￿
0.675
￿
+ +
MC
￿
6.51 x 10 7 ￿0 .830
￿
+ + +
JL
￿
8.08 x 10 1 ￿0 .055
￿
-
MM
￿
4.50 x 10 6 ￿0 .051
￿
-
BN
￿
4.13 x 10'
￿
0.336
￿
+
WS
￿
4.47 x 10 7 ￿0 .051
￿
-
CB
￿
5.88 x 10 7 ￿0 .120
￿
-
CC
￿
1 .50 x 10'
￿
0.177
￿
-
SC
￿
4.21 x 10 5 ￿0 .213
￿
-
SD
￿
1 .12 x 10'
￿
1 .031
￿
+ + + +
FM
￿
1 .02 x 10'
￿
0 .247
￿
-
GS
￿
1 .42 x 10 7 ￿0 .133
￿
-
NK
￿
ND
￿
0.163 -
RCS
￿
2.63 x 104 ￿1 .116
￿
+ + + +
NH IgG 11 ￿2 .80 x 10 3 ￿0 .018
￿
-
Id-RoI activity of anti-Ro/SSA IgG was measured by ELISA, and expressed as the average
OD oftwo separate determinations . Units of anti-Ro/SSA binding were also determined by
ELISA .
Id-Rol activity scale : - , <0.25 ;
￿
+, 0.26-0.50 ; + + , 0.51-0.75 ; + + + , 0.76-1 .00 ;
++++,>1.00 .
1 Immunizing anti-Ro/SSA .
4 Normal donor with elevated anti-Ro/SSA binding units by ELISA .
Normal human serum or Cohn fraction 11 IgG .GAITHER AND HARLEY
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have previously been reported for anti-Ro/SSA in SLE and SS. A growing body
of literature focusing on anti-DNA and rheumatoid factor idiotypes examines their
prevalence in patient populations (13), their role in pathogenesis (5, 6), and their
genetic basis (14). The development of an anti-Ro/SSA idiotype and the demonstra-
tion of shared reactivity is the first step towards evaluating differences between these
individuals on a molecular level. Idiotypic differences may explain variations be-
tween the clinical anti-Ro/SSA association in patient groups.
Summary
Idiotypes and antiidiotypes are thought to be important immune regulators and
have provided clues for the origin and pathogenicity of autoantibodies. Many lupus
and Sj6gren's syndrome patients, as well as most neonatal lupus infants with con-
genital heart block or dermatitis, have antibodies to the ribonucleoprotein Ro/SSA,
which is one of a group of RNA-protein autoantigens commonly found in human
lupus sera. To characterize the fine specificity of anti-Ro/SSA antibodies, a rabbit
antidiotypic serum was prepared against polyclonal affinity purified anti-Ro/SSA
F(aU)2 . The resulting antiidiotype, anti-Id-Rol, is specific for the F(ab')2 fraction
of the anti-Ro/SSA immunogen and its binding to anti-Ro/SSA is inhibited by purified
Ro/SSA. These data indicate that the Id-Rol epitope on anti-Ro/SSA is associated
with the antigen binding site ofthese same antibodies. The Id-Rol idiotype was present
by ELISA in 3 of 12 additional anti-Ro/SSA preparations from precipitin-positive
donor sera and in anti-Ro/SSA from one normal donor with low level antibody. This
is the first shared idiotype to be found in the human autoantibodies binding to this
RNA-protein antigen. Idiotypic differences between anti-Ro/SSA autoantibodies have
the potential to explain the variation in pathologic associations found in individuals
who develop this autoantibody specificity.
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